Recombinant Human Heavy Chain Ferritin Nanoparticles Serve as ROS Scavengers for the Treatment of Ischemic Stroke
Mi Qi,Yajuan Cheng,Ke Liu,Jingxing Cai,Tianyu Liu,Xiaoying Wu,Huili Tang,He Huang,Qinbiao Chen,Xiaoguang Zhou
DOI: https://doi.org/10.2147/ijn.s449606
IF: 7.033
2024-03-08
International Journal of Nanomedicine
Abstract:Mi Qi, Yajuan Cheng, Ke Liu, Jingxing Cai, Tianyu Liu, Xiaoying Wu, Huili Tang, He Huang, Qinbiao Chen, Xiaoguang Zhou The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, People's Republic of China Correspondence: Mi Qi; Xiaoguang Zhou, Tel +86-13510794978 ; +86-18818780760, Email ; Purpose: Ischemic stroke is a high-incidence disease that threatens human well-being. The potent neuroprotective effects render reactive oxygen species (ROS) scavengers potential agents for acute ischemic stroke therapy. Challenges such as inadequate permeability across the blood-brain barrier (BBB), limited half-life, and adverse effects hinder the widespread utilization of small molecule and inorganic ROS scavengers. Thus, there is an urgent demand for efficacious neuroprotective agents targeting ischemic stroke. Our study discovered the superoxide dismutase (SOD)-mimetic activity of recombinant human heavy chain ferritin (rHF) nanoparticles expressed from Escherichia coli ( E. coli ). Subsequent investigations delved into the ROS-scavenging proficiency of rHF within neural cells, its therapeutic efficacy against ischemic stroke, and the elucidation of its neuroprotective mechanisms. Methods: rHF protein nanoparticles were expressed in E. coli and purified via size-exclusion chromatography. The superoxide anion (•O 2 − ) scavenging SOD-mimetic activity of rHF nanoparticles was measured using a SOD detection kit. The ROS scavenging ability and protection effects against oxidative damage of rHF nanoparticles were studied in H 2 O 2 -induced PC12 cells. Therapeutic effects and neuroprotective mechanisms of rHF against ischemic stroke were investigated with transient middle cerebral artery occlusion (MCAO) reperfusion mice model. Results: rHF nanoparticles can eliminate excessive ROS in nerve cells and alleviate oxidative damage. The results of animal experiments demonstrated that rHF nanoparticles passed across BBB, reduced infarct areas in brain tissue, and lowered the neurological deficit score of ischemia-reperfusion model mice. Additionally, rHF nanoparticles mitigated neuronal apoptosis and ferroptosis, suppressed microglial activation, maintained oxygen homeostasis, and exhibited negligible organ toxicity. Conclusion: rHF nanoparticle could be developed as a new ROS scavenger for nerve cells and has therapeutic potential as a drug for cerebral ischemia-reperfusion injury. Keywords: human heavy chain ferritin, ROS scavenger, ischemic stroke, SOD-mimetic, neuroprotection Graphical Stroke is the second-leading cause of death and the third-leading cause of death and disability globally, and the incidence has increased continually in the past 30 years. 1 Ischemic stroke, accounting for almost 80% of all strokes, causes a constant medical burden to society. 2 Currently, the methods for ischemic stroke treatment include thrombolysis, thrombectomy, and neuroprotective therapies to restore cerebral blood flow and protect brain function. 3,4 Nonetheless, owing to the constrained therapeutic time window of 4.5 hours following the onset of stroke, only a minority of patients can avail themselves of timely and effective thrombolytic therapy. 5 In addition, the efficacy of these treatments is restricted by secondary damages mainly caused by oxidative stress, excitotoxicity, apoptosis, and neuroinflammation. 6,7 Reperfusion after thrombolytic therapy causes excessive production of harmful reactive oxygen species (ROS), such as superoxide anion radicals (•O 2 − ), hydroxyl radicals (•OH), hydrogen peroxide (H 2 O 2 ), and nitric oxide (NO), leading to increased neuronal death through protein oxidation, DNA damage, and lipid peroxidation. 8 Thus, ROS scavenging-based neuroprotective therapy becomes a leading strategy for ischemic stroke treatment. The application of small molecule radical scavengers (such as edaravone, 9 Dl-3-n-Butylphthalide, 10 and atorvastatin 11 ) and nano-antioxidants (such as CeO 2 nanoparticles, 12–14 melanin, 15 carbon dot, 16 platinum, 17 and manganese dioxide 18,19 ) have been proven as promising approaches for efficient treatments for stroke. Nevertheless, the clinical utilization of small-molecule ROS scavengers or nano-antioxidants is hampered by their abbreviated half-life, limited bioavailability, inadequate permeation across the blood-brain barrier (BBB), and potential off-target side effects. 20 Hence, the imperative need arises for the development of agents possessing robust ROS scavenging activity and favorable phy -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology